china biologic products inc
(CBPO:NASDAQ GS)
china biologic products inc (CBPO) Snapshot
|
Open
$26.35
|
Previous Close
$26.14
|
|
|
Day High
$26.48
|
Day Low
$26.35
|
|
|
52 Week High
03/19/13 - $31.15
|
52 Week Low
05/25/12 - $7.07
|
|
|
Market Cap
710.9M
|
Average Volume 10 Days
15.9K
|
|
|
EPS TTM
$1.69
|
Shares Outstanding
26.8M
|
|
|
EX-Date
--
|
P/E TM
15.7x
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
china biologic products inc (CBPO) Related Businessweek News
No Related Businessweek News Foundchina biologic products inc (CBPO) Details
China Biologic Products, Inc., a biopharmaceutical company, through its subsidiaries, engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People’s Republic of China. It offers human albumin for the treatment of shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also offers human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human albumin and human immunoglobulin for intravenous injection (IVIG) products for original immunoglobulin deficiency, secondary immunoglobulin deficiency, and auto-immune deficiency diseases; and Thymopolypeptides injection that is used for the treatment of various original and secondary T-cell deficiency syndromes, auto-immune deficiency diseases, and a range of cell immunity deficiency diseases, as well as assists in the treatment for tumors. In addition, it provides human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; human tetanus immunoglobulin for the prevention and therapy of tetanus; and placenta polypeptide that is used for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia caused by various reasons, as well as assists in postoperative heating. The company’s products under development comprise human prothrombin complex concentrate; human hepatitis B immunoglobulin (PH4) for intravenous injection; human fibrinogen; Varicella hyperimmune globulins; and Human IVIG. It distributes its products directly or through distributors. The company is based in Beijing, the People's Republic of China.
Last Reported Date: 03/13/13
china biologic products inc (CBPO) Top Compensated Officers
china biologic products inc (CBPO) Key Developments
China Biologic Products, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported sales of $54,031,732 against $47,227,461 a year ago. Income from operations was $25,978,392 against $18,829,245 a year ago. Earnings before income tax expense were $26,519,228 against $20,894,882 a year ago. Net income attributable to the company was $14,915,860 against $12,957,306 a year ago. Net income was $0.53 per diluted share of common stock against $0.44 diluted share of common stock a year ago. Net cash provided by operating activities was $22,030,185 against $8,208,202 a year ago. Payment for purchase of property, plant and equipment was $4,977,306 against $2,325,870 a year ago. Payment for purchase of intangible assets and land use right was $802,136 against $318,622 a year ago. Non-GAAP adjusted net income attributable to the company was $16,394,620 or $0.59 per diluted share against $12,710,343 or $0.48 per diluted share a year ago. For the full year of 2013, the company reiterates comfort with its full year financial forecast of total sales in the range of $195 million to $205 million and full year non-GAAP adjusted net income in the range of $50 million to $53 million. This guidance assumes the anticipated production suspension at the Company's Guizhou facility, only organic growth and excludes acquisitions and necessarily assumes no significant adverse product price changes during 2013.
China Biologic Products, Inc., Q1 2013 Earnings Call, May 09, 2013
China Biologic Products, Inc. announced that they will report Q1, 2013 results at 5:00 PM, China Standard Time on May 08, 2013
| Recently Viewed | |||
| CBPO:US | $26.48 USD | +0.34 |  |
| Company | Last | Change |
| Beijing Tiantan Biological Products Co | CNY17.69 CNY | +0.09 |
| Hualan Biological Engineering Inc | CNY25.20 CNY | +0.06 |
| Jiangxi Boya Bio-Pharmaceutical Co Ltd | CNY35.47 CNY | +0.46 |
| Neostem Inc | $0.59 USD | -0.0005 |
| Shanghai RAAS Blood Products Co Ltd | CNY21.05 CNY | 0.00 |
| View Industry Companies | ||
Industry Analysis
CBPO
Industry Average
| Valuation | CBPO | Industry Range |
| Price/Earnings | 15.1x |
|
| Price/Sales | 3.7x |
|
| Price/Book | 3.3x |
|
| Price/Cash Flow | 14.9x |
|
| TEV/Sales | 2.6x |
|
Post a JobJobs
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
- New York, NY | New York UniversityPosted: Apr 19
Sponsored Financial Commentaries
Sponsored Links
To contact CHINA BIOLOGIC PRODUCTS INC, please visit www.chinabiologic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
